Extended ischemic times during ex vivo lung perfusion is not associated with increased mortality

Abstract

AbstractBackgroundThe purpose of this study was to identify the association of increasing ischemic times in recipients who receive lungs evaluated by ex vivo lung perfusion (EVLP) and their association with outcomes following lung transplantation.MethodsLung transplant recipients who received an allograft evaluated by EVLP were identified from the United Network for Organ Sharing (UNOS) Database from 2016–2023. Recipients were stratified into three groups based on total ischemic time (TOT): short TOT (STOT, 0 to <7 h), medium TOT (MTOT, 7> to <14 h), and long TOT (LTOT, +14 h). The groups were assessed with comparative statistics and Kaplan–Meier methods. A Cox regression was created to determine the association of ischemic time in EVLP donors and long‐term mortality.ResultsRecipients in the LTOT group had significantly longer length of stay and post‐operative extracorporeal membrane use at 72 h (p < 0.05 for both). Additionally, they had nonsignificant increases in rate of stroke (4.7%, p = 0.05) and primary graft dysfunction grade 3 (PGD3, 27.5%, p = 0.082). However, there was no significant difference in hospital mortality or mid‐term survival (p > 0.05 for both). On multivariable analysis, ischemic time was not associated with increased mortality whereas increasing recipient age, preoperative ECMO use and donation after circulatory death donors were (p < 0.05 for all).ConclusionsIf EVLP technology is available, under certain circumstances, surgeons should not be dissuaded from using an allograft with extended ischemic time.